JP7783217B2 - アズブジンを含む抗腫瘍医薬組成物 - Google Patents

アズブジンを含む抗腫瘍医薬組成物

Info

Publication number
JP7783217B2
JP7783217B2 JP2023083308A JP2023083308A JP7783217B2 JP 7783217 B2 JP7783217 B2 JP 7783217B2 JP 2023083308 A JP2023083308 A JP 2023083308A JP 2023083308 A JP2023083308 A JP 2023083308A JP 7783217 B2 JP7783217 B2 JP 7783217B2
Authority
JP
Japan
Prior art keywords
tumor
egfr
cancer
azuvudine
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023083308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024125139A (ja
JP2024125139A5 (https=
Inventor
パン・リー
リミン・ジア
ジヨン・シン
ザオヤン・ワン
Original Assignee
ホーナン・ジェニュイン・バイオテック・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホーナン・ジェニュイン・バイオテック・カンパニー・リミテッド filed Critical ホーナン・ジェニュイン・バイオテック・カンパニー・リミテッド
Publication of JP2024125139A publication Critical patent/JP2024125139A/ja
Publication of JP2024125139A5 publication Critical patent/JP2024125139A5/ja
Application granted granted Critical
Publication of JP7783217B2 publication Critical patent/JP7783217B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023083308A 2023-03-03 2023-05-19 アズブジンを含む抗腫瘍医薬組成物 Active JP7783217B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310201580.X 2023-03-03
CN202310201580.XA CN116212030A (zh) 2023-03-03 2023-03-03 包含阿兹夫定的抗肿瘤药物组合物

Publications (3)

Publication Number Publication Date
JP2024125139A JP2024125139A (ja) 2024-09-13
JP2024125139A5 JP2024125139A5 (https=) 2025-03-31
JP7783217B2 true JP7783217B2 (ja) 2025-12-09

Family

ID=86468723

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023083308A Active JP7783217B2 (ja) 2023-03-03 2023-05-19 アズブジンを含む抗腫瘍医薬組成物

Country Status (7)

Country Link
US (1) US11878028B1 (https=)
EP (1) EP4424310B1 (https=)
JP (1) JP7783217B2 (https=)
KR (1) KR20250166964A (https=)
CN (1) CN116212030A (https=)
TW (1) TW202435855A (https=)
WO (1) WO2024183644A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020206603A1 (zh) 2019-04-09 2020-10-15 河南真实生物科技有限公司 2-(2，4，5-取代苯氨基)嘧啶衍生物及其晶形b
JP2021520389A (ja) 2018-04-06 2021-08-19 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’−環状ジヌクレオチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CN113171350B (zh) * 2015-06-03 2023-05-26 南京三迭纪医药科技有限公司 药品剂型及其使用
CN109562176A (zh) * 2016-04-15 2019-04-02 费利克斯疗法公司 使用静止细胞靶向和egfr抑制剂的用于治疗肿瘤的组合
TWI762784B (zh) * 2018-05-23 2022-05-01 大陸商江蘇恒瑞醫藥股份有限公司 Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN110003183A (zh) * 2019-04-09 2019-07-12 河南真实生物科技有限公司 2-（2，4，5-取代苯氨基）嘧啶衍生物及其晶形b
JP2023510426A (ja) * 2020-01-20 2023-03-13 アストラゼネカ・アクチエボラーグ 癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
CN114191558A (zh) * 2020-09-17 2022-03-18 上海翰森生物医药科技有限公司 Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途
CN114569728B (zh) * 2020-11-30 2023-11-28 诺未科技（北京）有限公司 一种组合物及其应用和药物
CN115006397A (zh) * 2021-03-05 2022-09-06 上海翰森生物医药科技有限公司 一种预防或治疗肿瘤疾病的药物用途
CN116212030A (zh) * 2023-03-03 2023-06-06 河南真实生物科技有限公司 包含阿兹夫定的抗肿瘤药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021520389A (ja) 2018-04-06 2021-08-19 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ２’３’−環状ジヌクレオチド
WO2020206603A1 (zh) 2019-04-09 2020-10-15 河南真实生物科技有限公司 2-(2，4，5-取代苯氨基)嘧啶衍生物及其晶形b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Frontiers in Oncology，2022年，12, 820647，pp.1-8，DOI: 10.3389/fonc.2022.820647
Journal of Medicinal Chemistry，2021年，64(2)，pp.925-937，DOI: 10.1021/acs.jmedchem.0c02205

Also Published As

Publication number Publication date
CN116212030A (zh) 2023-06-06
EP4424310A1 (en) 2024-09-04
JP2024125139A (ja) 2024-09-13
WO2024183644A1 (zh) 2024-09-12
KR20250166964A (ko) 2025-11-28
EP4424310C0 (en) 2025-07-16
US11878028B1 (en) 2024-01-23
EP4424310B1 (en) 2025-07-16
TW202435855A (zh) 2024-09-16

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
CA3222772A1 (en) Erk1/2 and shp2 inhibitors combination therapy
JP7783217B2 (ja) アズブジンを含む抗腫瘍医薬組成物
TW200412937A (en) Combination chemotherapy
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
EP4424316B1 (en) Antitumor pharmaceutical composition comprising azvudine and chemotherapeutic agent
US20170173023A1 (en) Combination therapy with volasertib
US10857146B2 (en) Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor
CN119343139A (zh) 治疗肿瘤的药物组合及用途
JP7381115B2 (ja) 組成物及びがん治療用医薬品の調製におけるその応用
CN118787649B (zh) 一种治疗非小细胞肺癌kras g12c突变的药物组合物及其应用
CN116159062A (zh) 药物组合物及其用途
CN111617081B (zh) 一种取代丁烯酰胺联合mTOR抑制剂的药物组合物及其用途
WO2023159184A1 (en) Drug combinations and methods of treating ovarian cancer
CN118302169A (zh) 治疗癌症或血液疾病的方法
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
Arena et al. Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients
WO2022104470A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
WO2025070603A1 (ja) 血液がんの新規併用療法
HK40059772A (en) Composition and application thereof in preparation of medicament for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250321

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251127

R150 Certificate of patent or registration of utility model

Ref document number: 7783217

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150